Articles tagged with “biosimilars”

FDA Purple Book Database: Biosimilar Data and Crosswalks

A 2026 guide to FDA Purple Book database fields, CSV downloads, reference-product joins and product-level interchangeability, with a verified crosswalk and reproducible snapshot counts.

25 min read

10/15/2026

fda purple book database fda purple book biosimilars interchangeable biosimilars reference products biologics data purple book csv regulatory intelligence biologics crosswalk

Sun Pharma $11.75B Organon Acquisition Strategic Analysis

Analyze Sun Pharma's $11.75B acquisition of Organon. This report examines deal mechanics, the women's health portfolio integration, and biosimilars strategy.

35 min read

5/8/2026

sun pharma organon acquisition pharmaceutical m&a women's health portfolio biosimilars specialty generics corporate strategy

2027 Drug Patent Expirations: LOE Calendar & Pipeline

Analyze 2027 drug patent expirations and the impending patent cliff. Review a detailed loss-of-exclusivity (LOE) calendar for biologics and small molecules.

25 min read

4/30/2026

drug patent expirations loss of exclusivity 2027 patent cliff loe calendar biosimilars generic drugs pharma pipeline biologics

Drug Patents Expiring in 2026: A Comprehensive Guide

An analysis of the 2026 drug patent cliff: selected U.S. patent expirations and generic-entry dates, including Januvia, Xeljanz and Ozempic, and their impact on generic drug prices.

25 min read

11/15/2025

patent expiration patent cliff 2026 generic drugs biosimilars pharmaceutical industry fda orange book ozempic patent januvia patent

Specialty Pharmacy: An Analysis of Key Players & Trends

An in-depth analysis of the specialty pharmacy industry covering key players (PBMs, distributors), market trends, biosimilar competition, PBM reform, and the economics of high-cost specialty drugs. Updated March 2026.

45 min read

11/3/2025

specialty pharmacy specialty drugs pharmacy benefit manager drug spending pbms gene therapy biosimilars